AVBP
NASDAQ · Biotechnology
Arrivent Biopharma Inc
$29.99
-1.10 (-3.54%)
Open$30.98
Previous Close$31.09
Day High$31.87
Day Low$29.51
52W High$32.14
52W Low$16.10
Volume—
Avg Volume462.5K
Market Cap1.34B
P/E Ratio—
EPS$-4.46
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
-14.6% upside
Current
$29.99
$29.99
Target
$25.60
$25.60
$15.99
$25.60 avg
$32.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 217.05M | 207.22M | 172.47M |
| Net Income | -33,899,494 | -32,015,874 | -32,580,881 |
| Profit Margin | -15.6% | -15.5% | -18.9% |
| EBITDA | -52,835,285 | -48,435,254 | -38,009,184 |
| Free Cash Flow | -36,657,940 | -37,197,569 | -30,385,570 |
| Rev Growth | +1.9% | +19.8% | +13.5% |
| Debt/Equity | 0.28 | 0.20 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |